FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 343:1641-1643 November 30, 2000 Number 22 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited Related Article by Mandel, J. S. PubMed Citation

It is well established that screening for colorectal cancer with the fecal occult-blood test significantly lowers the rate of death from the disease.¹ The report by Mandel et al.² in this issue of the Journal suggests that it also prevents cancer, reaffirming prior research about the benefits of detecting adenomatous polyps.³ The mounting evidence that early detection saves lives has sharpened the consensus among professional groups that screening for colorectal cancer should begin routinely at the age of 50.⁴

The current debate centers on which tests to use, at what ages, and how often. Each of the tests — fecal . . . [Full Text of this Article]

References

This article has been cited by other articles:

• Kiviniemi, M. T., Hay, J. L., James, A. S., Lipkus, I. M., Meissner, H. I., Stefanek, M., Studts, J. L., Bridges, J. F.P., Close, D. R., Erwin, D. O., Jones, R. M., Kaiser, K., Kash, K. M., Kelly, K. M., Craddock Lee, S. J., Purnell, J. Q., Siminoff, L. A., Vadaparampil, S. T., Wang, C. (2009). Decision Making about Cancer Screening: An Assessment of the State of the Science and a Suggested Research Agenda from the ASPO Behavioral Oncology and Cancer Communication Special Interest Group. Cancer Epidemiol. Biomarkers Prev. 18: 3133-3137 [Full Text]  
• Ma, Y., Peng, J., Liu, W., Zhang, P., Huang, L., Gao, B., Shen, T., Zhou, Y., Chen, H., Chu, Z., Zhang, M., Qin, H. (2009). Proteomics Identification of Desmin as a Potential Oncofetal Diagnostic and Prognostic Biomarker in Colorectal Cancer. Mol. Cell. Proteomics 8: 1878-1890 [Abstract] [Full Text]  
• Subramanian, S., Bobashev, G., Morris, R. J. (2009). Modeling the Cost-Effectiveness of Colorectal Cancer Screening: Policy Guidance Based on Patient Preferences and Compliance. Cancer Epidemiol. Biomarkers Prev. 18: 1971-1978 [Abstract] [Full Text]  
• Levin, T. R., Zhao, W., Conell, C., Seeff, L. C., Manninen, D. L., Shapiro, J. A., Schulman, J. (2006). Complications of Colonoscopy in an Integrated Health Care Delivery System. ANN INTERN MED 145: 880-886 [Abstract] [Full Text]  
• Roessler, M., Rollinger, W., Mantovani-Endl, L., Hagmann, M.-L., Palme, S., Berndt, P., Engel, A. M., Pfeffer, M., Karl, J., Bodenmuller, H., Ruschoff, J., Henkel, T., Rohr, G., Rossol, S., Rosch, W., Langen, H., Zolg, W., Tacke, M. (2006). Identification of PSME3 as a Novel Serum Tumor Marker for Colorectal Cancer by Combining Two-dimensional Polyacrylamide Gel Electrophoresis with a Strictly Mass Spectrometry-based Approach for Data Analysis. Mol. Cell. Proteomics 5: 2092-2101 [Abstract] [Full Text]  
• Roessler, M., Rollinger, W., Palme, S., Hagmann, M.-L., Berndt, P., Engel, A. M., Schneidinger, B., Pfeffer, M., Andres, H., Karl, J., Bodenmuller, H., Ruschoff, J., Henkel, T., Rohr, G., Rossol, S., Rosch, W., Langen, H., Zolg, W., Tacke, M. (2005). Identification of Nicotinamide N-Methyltransferase as a Novel Serum Tumor Marker for Colorectal Cancer. Clin. Cancer Res. 11: 6550-6557 [Abstract] [Full Text]  
• Hawk, E. T., Levin, B. (2005). Colorectal Cancer Prevention. JCO 23: 378-391 [Abstract] [Full Text]  
• Zapka, J. G., Lemon, S. C., Puleo, E., Estabrook, B., Luckmann, R., Erban, S. (2004). Patient Education for Colon Cancer Screening: A Randomized Trial of a Video Mailed before a Physical Examination. ANN INTERN MED 141: 683-692 [Abstract] [Full Text]  
• Whynes, D. K. (2002). The economic case for faecal occult blood screening. Ann Oncol 13: 1953-1955 [Full Text]  
• Swaroop, V. S., Larson, M. V. (2002). Colonoscopy as a Screening Test for Colorectal Cancer in Average-Risk Individuals. Mayo Clin Proc. 77: 951-956 [Abstract]  
• Anderson, W. F., Guyton, K. Z., Hiatt, R. A., Vernon, S. W., Levin, B., Hawk, E. (2002). Colorectal Cancer Screening for Persons at Average Risk. JNCI J Natl Cancer Inst 94: 1126-1133 [Full Text]  
• Pignone, M., Saha, S., Hoerger, T., Mandelblatt, J. (2002). Cost-Effectiveness Analyses of Colorectal Cancer Screening: A Systematic Review for the U.S. Preventive Services Task Force. ANN INTERN MED 137: 96-104 [Abstract] [Full Text]  
• Pignone, M., Rich, M., Teutsch, S. M., Berg, A. O., Lohr, K. N. (2002). Screening for Colorectal Cancer in Adults at Average Risk: A Summary of the Evidence for the U.S. Preventive Services Task Force. ANN INTERN MED 137: 132-141 [Abstract] [Full Text]  
• Barry, M. J. (2002). Fecal occult blood testing for colorectal cancer: a perspective. Ann Oncol 13: 61-64 [Abstract] [Full Text]  
• Ransohoff, D. F., Sandler, R. S. (2002). Screening for Colorectal Cancer. NEJM 346: 40-44 [Full Text]  
• Pesce, A. (2001). Colorectal cancer screening. Fam Pract 18: 457-460 [Full Text]  
• (2001). Occult Blood Screening Reduces Risk for Colorectal Cancer. Journal Watch Dermatology 2001: 8-8 [Full Text]  
• (2000). Occult Blood Screening Reduces Risk for Colorectal Cancer. JWatch General 2000: 1-1 [Full Text]